| 何飞,胡钦,李志会,仲成,晏露宁,邓旻.中医辨证论治与协定方治疗重型新型冠状病毒肺炎的回顾性研究[J].浙江中西医结合杂志,2022,32(6): |
| 中医辨证论治与协定方治疗重型新型冠状病毒肺炎的回顾性研究 |
| Retrospective study on the treatment of severe corona virus disease2019 with syndrome differentiation and agreed prescription of traditional Chinese medicine |
| 投稿时间：2021-09-01 修订日期：2022-03-15 |
| DOI： |
| 中文关键词: 新型冠状病毒肺炎 协定方 辨证论治 回顾性研究 |
| 英文关键词:corona virus disease2019 the agreement prescription treatment based on syndrome differentiation retrospective study |
| 基金项目:杭州市科技发展计划(20200706B03)； |
|
| 摘要点击次数: 865 |
| 全文下载次数: 11 |
| 中文摘要: |
| 目的 回顾性分析47例重型新型冠状病毒肺炎患者的临床资料,探讨中西医结合治疗新型冠状病毒肺炎的临床疗效。方法 收集2020年2月1日-2020年 3月29日在武汉同济医院光谷院区和武汉第四医院出院的47例新型冠状病毒肺炎患者资料,按治疗方案分成西医组(15例)、协定方组(16例)和辨证论治组(16例)。西医组使用呼吸支持、抗病毒药物及其他对症治疗。协定方组在西医组治疗基础上加用化湿解毒汤治疗。辨证论治组在西医组治疗基础上,根据临床资料辨证论治给予中药。比较三组中医症候积分、实验室指标、肺部CT病灶好转率、临床治愈率、危重症转化率及死亡率等。结果 与西医组比较,辨证论治组中医症候积分改善、临床治愈率、治疗后中性粒细胞与淋巴细胞比值(NLR)改善均显著优于西医组(P<0.05)。三组在D-D聚体值、肺部CT病灶好转率、危重症转化率及死亡率等方面差异无统计学意义(P>0.05)。结论 中西医结合治疗特别是辨证论治中医治疗重型新型冠状病毒肺炎能显著减轻患者的临床症状,改善实验室指标,提高临床治愈率,值得推广应用。 |
| 英文摘要: |
| Objective: To retrospectively analyze the clinical data of 47 patients with severe type of corona virus disease2019(COVID-19), and to explore the clinical efficacy of integrated traditional Chinese and western medicine in the treatment of severe type of COVID-19. Methods:The data of 47 patients with COVID-19 discharged from the Guanggu District of Wuhan Tongji Hospital and Wuhan Fourth Hospital from February 1, 2020 to March 29, 2020 were collected and divided into western medicine groups (15 cases) 、agreement prescription group (16 cases) and syndrome differentiation group (16 cases) according to the treatment plan. The western medicine group was treated with respiratory support, antiviral drugs and other symptomatic treatments. On the basis of the western medicine group, the agreement group was treated with Huashi Jiedu Decoction. The group of treatment based on syndrome differentiation was based on the treatment of the western medicine group, and traditional Chinese medicine prescriptions were given according to the clinical data. Compare the three groups of TCM syndrome scores, laboratory indicators, lung CT lesion improvement rate, clinical cure rate, critical illness conversion rate, and mortality rate. Results: Compared with the western medicine group, the improvement of TCM syndrome score, the clinical cure rate, and the neutrophil to lymphocyte ratio (NLR) in the group of treatment based on syndrome differentiation were significantly better than the western medicine group (P<0.05). There was no significant difference among the three groups in terms of D-D polymer value, lung CT lesion improvement rate, critical illness conversion rate and mortality rate (P>0.05). Conclusion Integrated Chinese and Western medicine treatment, especially the treatment based on syndrome differentiation of severe type of COVID-19, can significantly reduce the clinical symptoms of patients, improve laboratory indicators, and increase the clinical cure rate. It is worthy of popularization and application.. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
